Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 558 participants.

Also called NCT06072001

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 558 participants (planned count) (from the registry)
Sponsor
Apurano Pharmaceuticals GmbH (from the registry)
Registry
  • NCT NCT06072001
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06072001. Randomized; quadruple masking; primary purpose treatment. Start 2023-11-02 (actual); primary completion 2024-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Condition
Pain
Condition
Pain Syndrome
Condition
Pain, Chronic
Condition
Chronic Pain
Condition
Chronic Pain Syndrome
Condition
Neuropathic Pain
Condition
Central Neuropathic Pain
Condition
Paraplegia
Condition
Multiple Sclerosis
Condition
Stroke
Condition
Phantom Limb Syndrome With Pain
Condition
Phantom Pain
Condition
Traumatic Brain Injury
Intervention (Drug)
Adezunap (AP707)
Intervention (Drug)
Placebo
Lead sponsor
Apurano Pharmaceuticals GmbH (class: industry)

Record details

Record id
cardio:ct-nct06072001
Content hash
6fb47683c7a4b90f1cf85e46b30e7cb17e86b4e96191900bb12aeedace110daa